4.3 Article

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry

Related references

Note: Only part of the references are listed.
Article Critical Care Medicine

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu et al.

Summary: This article provides updates on the guidelines for idiopathic pulmonary fibrosis (IPF) and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. The recommendations are based on consensus and systematic reviews, aiming to provide evidence-based guidance for clinicians.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Review Medicine, Research & Experimental

Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey

Amy Olson et al.

Summary: Through a systematic review of ILD prevalence, it was found that 13-40% of ILDs may progress to a fibrosing phenotype, with overall prevalence estimates of 2.2-20.0 per 100,000 in Europe and 28.0 per 100,000 in the USA for progressive fibrosing ILDs. Prevalence estimates for individual progressive fibrosing ILDs varied up to 16.7 per 100,000 people. These conditions represent a significant portion of chronic respiratory disorders and have high unmet needs.

ADVANCES IN THERAPY (2021)

Review Critical Care Medicine

Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis A Systematic Review and Meta-Analysis

Tananchai Petnak et al.

Summary: Meta-analysis of 26 studies showed that antifibrotic treatment reduced the risk of all-cause mortality and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).

CHEST (2021)

Review Cardiac & Cardiovascular Systems

Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases

Corey D. Kershaw et al.

Summary: Acute exacerbations of fibrosing interstitial lung disease can occur in both idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs, but the incidence in non-IPF ILDs is likely lower. Both entities share similar risk factors, but lack a consistent definition for non-IPF ILD exacerbations. Corticosteroids are commonly used in treatment, with uncertain evidence of benefit. There is currently no proven therapy for acute ILD exacerbations.

RESPIRATORY MEDICINE (2021)

Article Medicine, General & Internal

Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Paola Faverio et al.

Summary: The study retrospectively analyzed a cohort of 158 adult patients hospitalized for acute exacerbation-ILD in two Italian university hospitals from 2009 to 2016 and found that non-specific interstitial pneumonia and connective tissue disease-ILD were the most common diagnoses in the non-IPF group, while the IPF group had a higher mortality rate. Increasing inflammatory markers, presence of pulmonary hypertension, and IPF diagnosis were identified as negative prognostic factors, while lymphocytosis was seen as a protective prognostic factor. Further research is needed to confirm these findings.

DIAGNOSTICS (2021)

Article Respiratory System

Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry

Jing Gao et al.

Summary: Observational data from the Swedish IPF Registry showed that anti-fibrotic treatment, disease severity, and phenotypes are closely associated with outcomes of patients with idiopathic pulmonary fibrosis (IPF). Treated patients had better survival rates, with specific physiological factors and phenotypes playing a role in predicting outcomes.

RESPIRATORY RESEARCH (2021)

Article Respiratory System

The natural history of progressive fibrosing interstitial lung diseases

K.K. Brown et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Article Respiratory System

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis

J. H. Fisher et al.

BMC PULMONARY MEDICINE (2019)

Review Respiratory System

Acute exacerbations of progressive-fibrosing interstitial lung diseases

Martin Kolb et al.

EUROPEAN RESPIRATORY REVIEW (2018)

Article Critical Care Medicine

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report

Claus F. Vogelmeier et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)

Article Critical Care Medicine

Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences

Motoki Natsuizaka et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)

Article Respiratory System

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials

Harold R. Collard et al.

RESPIRATORY RESEARCH (2013)

Article Critical Care Medicine

An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Article Respiratory System

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

C. J. Zappala et al.

EUROPEAN RESPIRATORY JOURNAL (2010)

Article Respiratory System

A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis

O. Nishiyama et al.

EUROPEAN RESPIRATORY JOURNAL (2010)

Article Critical Care Medicine

Acute exacerbations of idiopathic pulmonary fibrosis

Harold R. Collard et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)

Article Cardiac & Cardiovascular Systems

Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis

K Jeon et al.

RESPIRATORY MEDICINE (2006)